Shots:

• The companies have launched Fulphila- a biosimilar referencing Neulasta (pegfilgrastim) and is approved by Health Canada to decrease the incidence of infection- as manifested by febrile neutropenia- in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs
• The approval is based on analytical- non/clinical data- which showed that Fulphila is highly similar to Neulasta with no clinically meaningful differences in terms of safety and efficacy
• The launch will expand biosimilar access to the patients in Canada- following the successful launch of Fulphila in the US. This is the second biosimilar to be launched in Canada under Mylan and Biocon collaboration

Click here ­to­ read full press release/ article | Ref: Biocon | Image: Mylan

Related News: Biocon and Mylan Launch Fulphila (biosimilar- Pegfilgrastim) in Australia